Aastrom Moves Cell Therapy Into Phase III
This article was originally published in The Pink Sheet Daily
The biotech talked about its late-stage clinical plans during a second quarter conference call.
You may also be interested in...
The stem cell company will use revenues from the already-marketed products to continue funding the late-stage stem cell therapy in its pipeline and help it build out its commercial organization.
The Michigan biotech is undergoing a complete restructuring as it cans its lead program and new management implements a different vision for the company.
The genome engineering company, Cellectis, is to acquire the Swedish human embryonic stem cell firm Cellartis in a €30 million deal expected to complete at the end of October.